Catherine Shaffer

Ann Arbor, MI USA
Contact

Professional Experience

I'm a freelance science journalist with thirteen years experience specializing in the pharmaceutical industry and biotechnology. I also have experience with food science, environmental science, and local beat journalism. Basically, I've done it all--features, news, technical reports, broadcast radio. I'm a reliable and versatile writer who takes deadlines seriously and views criticism and feedback as an opportunity to do a better job for my client.

Expertise

Reporter
13 Years
Writer
13 Years

Specialty

Fiction
20 Years
Business (general)
13 Years
Science
13 Years

Industries


Magazine - Large Consumer/National magazines
13 Years
Magazine - Trade magazines/publications (B2B)
13 Years
Newspaper - Local/Regional
13 Years

Total Media Industry Experience

20 Years

Media Client List (# assignments last 2 yrs)

BioCentury (10+), BioWorld Today (10+), Michigan Radio (10+)

Corporate Client List (# assignments last 2 yrs)

Siemens (1-2)

Other Work History

Food Quality, Genetic Engineering and Biotechnology News, Drug Discovery and Development, Genomics and Proteomics, Biocompare, Labcompare, Nature Biotechnology, Nature Medicine, Pharmacy Practice News, Tech Comm Journal, Analog Science Fiction and Fact

Technical Skills

Audio editing (Adobe Audition, Newsboss), Web Design (Dreamweaver)

Computer Skills

Microsoft Office, OpenOffice, Adobe Acrobat, Adobe Incopy

Equipment

Laptop, digital camera

References

Available upon request

Awards

National Merit Scholar Honorable Mention, L. Ron Hubbard's Writers of the Future Contest Anlab Readers Award, Analog Science Fiction and Fact, Best Science Fact Article, “If a Tree Falls...the Secret History of Global Environmental Catastrophe” Anlab Readers Award, Analog Science Fiction and Fact, Best Short Story, “Titanium Soul”

Showcase

Biotech

Flagship Ventures, Polaris Partners and Third Rock Ventures have teamed up to fund a biotech start-up based on a genome-editing platform to the tune of $43 million in Series A financing. The Cambridge, Mass.-based company, Editas Medicine, said its technology has the potential to use RNA molecules..